Gary W. Middleton
Expertise in
5
conditions

Gary W. Middleton

Birmingham, ENG, GB 
Expertise in
5
conditions
Birmingham, ENG, GB 

Overview

Gary Middleton practices practicing medicine in Birmingham, United Kingdom.

Mr. Middleton is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, and Pancreatic Cancer.

He is actively involved in clinical research, co-authoring 105 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

Birmingham, ENG, United Kingdom
Other Locations
Guildford, ENG, United Kingdom
St. Luke's Cancer Centre, Ashford And St. Peters' Hospitals, Oxford, ENG, United Kingdom
Edgbaston, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer
National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: April 28, 2026
Intervention Type: Drug
Study Drugs: AZD4547, Vistusertib, Palbociclib, Crizotinib, Selumetinib, Docetaxel, AZD5363, Osimertinib, Durvalumab, Sitravatinib, AZD6738
Study Phase: Phase 2
A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 22, 2026
Intervention Type: Drug
Study Phase: Phase 2
A Prospective, Phase II, Double Blinded, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Vandetanib Therapy With Gemcitabine Therapy Alone in Locally Advanced or Metastatic Pancreatic Carcinoma
A Prospective, Phase II, Double Blinded, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Vandetanib Therapy With Gemcitabine Therapy Alone in Locally Advanced or Metastatic Pancreatic Carcinoma
Enrollment Status: Completed
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drug: Caprelsa (Vandetanib)
Study Phase: Phase 2
A Phase I/IIa, Multicentre, Two Parts, Open-Label Study Designed to Evaluate the Safety and Tolerability of Escalating Doses of AGI-134 in Unresectable/Metastatic Solid Tumours
A Phase I/IIa, Multicentre, Two Parts, Open-Label Study Designed to Evaluate the Safety and Tolerability of Escalating Doses of AGI-134 in Unresectable/Metastatic Solid Tumours
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I Trial of WEE1 Inhibition with Chemotherapy and Radiotherapy As Adjuvant Treatment, and a Window of Opportunity Trial with Cisplatin in Patients with Head and Neck Cancer
A Phase I Trial of WEE1 Inhibition with Chemotherapy and Radiotherapy As Adjuvant Treatment, and a Window of Opportunity Trial with Cisplatin in Patients with Head and Neck Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Radiation
Study Phase: Phase 1
A Phase Ib/IIa Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers
A Phase Ib/IIa Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers
Enrollment Status: Unknown
Publish Date: February 25, 2020
Intervention Type: Drug
Study Drugs: AZD2014, Selumetinib
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

105 Total Publications

Severe Toxic Epidermal Necrolysis Following Combination Ipilimumab-Nivolumab Therapy for Pleural Mesothelioma, Successfully Treated With Ruxolitinib: A Case Report.
Severe Toxic Epidermal Necrolysis Following Combination Ipilimumab-Nivolumab Therapy for Pleural Mesothelioma, Successfully Treated With Ruxolitinib: A Case Report.
Journal: Clinical lung cancer
Published: February 06, 2026

Frequently Asked Questions about Gary W. Middleton

Is Gary W. Middleton a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Gary W. Middleton is classified as an Advanced expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Gary W. Middleton participate in research or clinical trials?

Yes. Gary W. Middleton has published 105 articles and abstracts on conditions like Lung Cancer. You can view a list of Gary W. Middleton's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Middleton's expertise for a condition
ConditionClose
      View All 15 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile